New drug ALXN2230 gets first human safety check

NCT ID NCT07352423

Recruiting now Knowledge-focused Sponsor: Alexion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a single dose of ALXN2230 in 48 healthy adults to see if it is safe and how the body processes it. Participants receive either the drug or a placebo by injection. The goal is to check for side effects and measure drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ALXN2230
What could go wrong: This is a very early, small study in healthy people, not patients. It only checks safety and how the drug moves in the body. There is no guarantee it will work for any disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULT PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY ADULT PARTICIPANTS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Research Site
RECRUITING

London, NW10 7EW, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.